Background: Pulmonary Arterial Hypertension (PAH) is a chronic disease which may cause
or result from multiple cardiopulmonary disorders. The disease has complex pathophysiological
mechanisms and involves many systematic, cellular and molecular changes. Therefore, it is crucial to
find out underlying mechanisms and detect biomarkers to achieve early and proper diagnosis, evaluating
disease severity, for follow-up and monitor response to treatment. Many biomarkers for PAH have
been investigated but yet no such biomarker has been found specific and easily accessible to use for
the patients. This review aims to identify an expanding role of biomarkers in PAH.
Method: We searched an expanding role of biomarkers such as asymmetric dimethylarginine
(ADMA), von Willebrand factor (vWF) and endothelin for PAH in the literature.
Results: Thirty-four actual papers were included in this review for searching an expanding role of biomarkers
in the PAH.
Conclusion: The search for a proper biomarker for PAH patients is an ongoing process. Currently we
do not have a PAH-specific, easily accesible, low-priced biomarker for PAH patients. One of the reasons
of that is that PAH has a complex etiology and the diesase eventually alters multiple systems. So
far, only BNP/NT-proBNP has been mainly approved and widely used for risk assesment in patients
with PAH. Ongoing studies, development in the technology and understanding the underlying mechanisms
in the pathophysiology of PAH, will eventually lead us to find proper biomarker(s), for PAH,
which will also improve patient outcomes and decrease treatment costs in PAH.